P27KIP1 EXPRESSION, A PROGNOSTIC INDICATOR==BUT WHY?
P27KIP1 表达,一个预后指标==但是为什么呢?
基本信息
- 批准号:6233528
- 负责人:
- 金额:$ 35.17万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-01-20 至 2005-12-31
- 项目状态:已结题
- 来源:
- 关键词:apoptosis breast neoplasms cell cycle proteins cyclin dependent kinase cyclins dopamine receptor enzyme inhibitors gene expression laboratory mouse neoplasm /cancer genetics neoplastic growth oncoproteins p53 gene /protein pituitary neoplasms prognosis prostate neoplasms protein kinase retinoblastoma protein
项目摘要
The goal of this proposal is to understand why the loss of p27kip1
expression is a strong prognostic indicator for tumor development in many types
of human cancer. This proposal examines two alternative hypotheses: First, that
the loss of p27 may accelerate cell proliferation making the cell refractory to
the negative growth influences of the surrounding cells; or second, that the
loss of p27 may eliminate oncogene-induced apoptosis by "desensitizing" the
cell to negative growth regulatory signals. In Aim 1, these two models will be
examined in the development of pituitary tumors in Rb+/- and Rb+/-;p27-/- mice.
Aim 2 will investigate the relationship between p27-deficiency and p53-mdm2-Arf
induced apoptosis in the pituitary tumor mouse model, and in human breast and
prostate tumor samples. Aim 3 will characterize the growth, apoptosis and
transformation properties of mouse embryonic fibroblasts derived from
Rb-/-;p27-/- embryos. A 4th Aim is proposed in the supplementary information
that is based on the recent finding of Adenocarcinomas in
p107+/-;p130-/-;p27-/- mice. This section will extend the analysis of
Rb+/-;p27-/- mice to other pocket protein/p27 combinations to determine how
loss of p27 modulates their tumor suppressor properties.
这项研究的目的是了解为什么p27 kip 1基因的缺失
在许多类型中,表达是肿瘤发展的强预后指标
人类癌症这一建议审查了两个备选假设:第一,
p27的缺失可加速细胞增殖,
周围细胞的负面生长影响;或者第二,
p27的缺失可能通过“脱敏”癌基因而消除癌基因诱导的凋亡。
细胞负生长调节信号。在目标1中,这两个模型将
在Rb+/-和Rb+/-;p27-/-小鼠垂体瘤的发展中进行了检查。
目的2探讨p27缺陷与p53-mdm 2-Arf的关系
在垂体瘤小鼠模型和人乳腺癌中诱导细胞凋亡,
前列腺肿瘤样本。目的3将描述生长,凋亡和
小鼠胚胎成纤维细胞的转化特性
Rb-/-;p27-/-胚胎。补充资料中提出了第四个目标
这是基于最近发现的腺癌,
p107+/-;p130-/-;p27-/-小鼠。本节将扩展对
Rb+/-;p27-/-小鼠与其他口袋蛋白/p27组合,以确定如何
p27的缺失调节其肿瘤抑制特性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANDREW KOFF其他文献
ANDREW KOFF的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANDREW KOFF', 18)}}的其他基金
CDK4 Inhibitor Therapy: Identification of Biomarkers and Combination Therapies for Liposarcoma
CDK4 抑制剂疗法:脂肪肉瘤生物标志物的鉴定和联合疗法
- 批准号:
10247698 - 财政年份:2018
- 资助金额:
$ 35.17万 - 项目类别:
CDK4 Inhibitor Therapy: Identification of Biomarkers and Combination Therapies for Liposarcoma
CDK4 抑制剂疗法:脂肪肉瘤生物标志物的鉴定和联合疗法
- 批准号:
10468963 - 财政年份:2018
- 资助金额:
$ 35.17万 - 项目类别:
CDK4 Inhibitor Therapy: Identification of Biomarkers and Combination Therapies for Liposarcoma
CDK4 抑制剂疗法:脂肪肉瘤生物标志物的鉴定和联合疗法
- 批准号:
10016097 - 财政年份:2018
- 资助金额:
$ 35.17万 - 项目类别:
P27KIP1 EXPRESSION, A PROGNOSTIC INDICATOR==BUT WHY?
P27KIP1 表达,一个预后指标==但是为什么呢?
- 批准号:
6693775 - 财政年份:2001
- 资助金额:
$ 35.17万 - 项目类别:
P27KIP1 EXPRESSION, A PROGNOSTIC INDICATOR==BUT WHY?
P27KIP1 表达,一个预后指标==但是为什么呢?
- 批准号:
6833487 - 财政年份:2001
- 资助金额:
$ 35.17万 - 项目类别:
相似海外基金
Pathology of Breast Neoplasms determined by MRS
MRS 测定乳腺肿瘤的病理学
- 批准号:
nhmrc : 950215 - 财政年份:1995
- 资助金额:
$ 35.17万 - 项目类别:
NHMRC Project Grants














{{item.name}}会员




